Stockreport

CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Legend Biotech Corporation - American Depositary Shares  (LEGN) 
PDF New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech [Read more]